Ligand Pharmaceuticals Inc (LGND) has disclosed a new risk, in the Competition category.
Ligand Pharmaceuticals Inc. confronts significant competitive pressures in its quest to acquire high-quality royalties, a key business strategy for the company’s growth. The market presents a scant selection of attractive royalty acquisition opportunities, which has led to a fiercely competitive environment. Ligand vies with an array of formidable competitors, such as product-marketing companies, financial institutions, and other entities that might possess advantages like lower capital costs, greater size, pre-existing strategic relationships, or a tolerance for lower return thresholds, potentially outpacing Ligand in securing valuable royalty deals.
The average LGND stock price target is $116.33, implying 47.81% upside potential.
To learn more about Ligand Pharmaceuticals Inc’s risk factors, click here.
